BerGenBio Second Quarter Results 2024: Solid clinical and financial progress ...Middle East

PR Newswire - News
BERGEN, Norway, Aug. 21, 2024 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the quarter and half year ended June 30, 2024, and...

Hence then, the article about bergenbio second quarter results 2024 solid clinical and financial progress was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( BerGenBio Second Quarter Results 2024: Solid clinical and financial progress )

Apple Storegoogle play

Last updated :

Also on site :



Latest News